MADRID, 12 Dic. (EUROPA PRESS) –
PharmaMar has received a payment of 10 million dollars (9.5 million euros) from Janssen Products LP upon reaching a commercial milestone established in the license agreement for Yondelis (trabectedin) in the United States, as announced on Monday .
In August 2019, PharmaMar signed a new license agreement with Janssen that replaced the 2001 one, under which the latter reserved the right to sell and distribute Yondelis exclusively in the United States.
Yondelis is currently approved in more than 70 countries for the treatment of soft tissue sarcoma and also in some of these countries for ovarian cancer.
